We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-29.17%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$186M
AUM Growth
+$106M
Cap. Flow
+$5.12M
Cap. Flow %
2.76%
Top 10 Hldgs %
78.1%
Holding
120
New
32
Increased
25
Reduced
31
Closed
26

Top Buys

Rank Stock Value
1
TEUM
Pareteum Corporation
TEUM
+$5.9M
2
HIND
Vyome Holdings
HIND
+$3.25M
3
CRMD icon
CorMedix
CRMD
+$2.09M
4
TRAW icon
Traws Pharma
TRAW
+$1.84M
5
XBIO icon
Xenetic Biosciences
XBIO
+$1.45M

Top Sells

Rank Stock Value
1
AMPE
Ampio Pharmaceuticals Inc.
AMPE
+$2.04M
2
SHIPW
Seanergy Maritime Holdings Corp Class A Warrants
SHIPW
+$1.54M
3
ODT
Odonate Therapeutics, Inc. Common Stock
ODT
+$1.35M
4
BCLI
BRAINSTORM CELL THERAPUTC
BCLI
+$622K
5
CANF
Can-Fite BioPharma American Depositary Shares
CANF
+$610K

Sector Composition

Rank Sector Weight
1 Healthcare 14.92%
2 Technology 1.81%
3 Industrials 0.77%
4 Consumer Discretionary 0.32%
5 Real Estate 0.2%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$783B
$29.6M 15.96%
998
+78
+8% +$23K
OEF icon
2
PUT
iShares S&P 100 ETF
OEF
$19.8B
$23.9M 12.87%
1,578
-978
-38% -$128K
OEF icon
3
CALL
iShares S&P 100 ETF
OEF
$19.8B
$23.7M 12.75%
1,563
+1,067
+215% +$140K
GLD icon
4
CALL
SPDR Gold Trust
GLD
$131B
$21.4M 11.56%
+2,428
New +$338K
IONS icon
5
CALL
Ionis Pharmaceuticals
IONS
$9.14B
$18.2M 9.81%
3,038
+267
+10% +$17.4K
SPY icon
6
CALL
State Street SPDR S&P 500 ETF Trust
SPY
$783B
$15M 8.08%
+505
New +$149K
XNTK icon
7
PUT
State Street SPDR NYSE Technology ETF
XNTK
$2B
$3.87M 2.08%
507
-347
-41% -$25.6K
AMRN
8
PUT
Amarin Corp
AMRN
$293M
$3.48M 1.88%
115
-10
-8% -$3.49K
AMRN
9
CALL
Amarin Corp
AMRN
$293M
$2.9M 1.57%
96
+86
+860% +$30K
TEUM
10
DELISTED
Pareteum Corporation
TEUM
$2.9M 1.56%
+2,248,578
New +$5.9M
ODT
11
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$2.42M 1.3%
92,854
-40,251
-30% -$1.35M
ATNM icon
12
Actinium Pharmaceuticals
ATNM
$27.2M
$2.02M 1.09%
293,250
+15,126
+5% +$105K
BHVN
13
PUT
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$1.72M 0.93%
+412
New +$17.4K
CRMD icon
14
CorMedix
CRMD
$577M
$1.59M 0.86%
+249,198
New +$2.09M
RDGT
15
Ridgetech Inc
RDGT
$1.04M
$1.59M 0.86%
37
-14
-27% -$566K
GNCA
16
DELISTED
Genocea Biosciences, Inc.
GNCA
$1.38M 0.75%
477,351
-16,824
-3% -$57.4K
NMTR
17
DELISTED
9 Meters Biopharma
NMTR
$1.34M 0.72%
62,441
-4,371
-7% -$88.3K
HIND
18
Vyome Holdings
HIND
$14M
$1.33M 0.72%
+1
New +$3.25M
ARCT icon
19
Arcturus Therapeutics
ARCT
$163M
$1.28M 0.69%
+124,843
New +$1.35M
CRMD icon
20
PUT
CorMedix
CRMD
$577M
$1.24M 0.67%
1,936
-2,697
-58% -$22.7K
BCLI
21
PUT
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
$1.02M 0.55%
174
+41
+31% +$2.42K
BNTC icon
22
Benitec Biopharma
BNTC
$408M
$971K 0.52%
+5,355
New +$984K
PAVMZ
23
DELISTED
PAVmed Inc. Series Z Warrant
PAVMZ
$949K 0.51%
2,964,629
-305,700
-9% -$104K
AUPH icon
24
CALL
Aurinia Pharmaceuticals
AUPH
$1.92B
$896K 0.48%
1,677
+771
+85% +$4.67K
PULM icon
25
Pulmatrix
PULM
$6.14M
$866K 0.47%
52,934
-426
-0.8% -$7.46K
1
2 3 4 5

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q3 2019 Portfolio in Review

As of Q3 2019, Sabby Management held 120 positions worth $186M, up 133% from $79.5M the previous quarter. Its ten largest holdings account for 78% of the portfolio.

Sabby Management's Q3 2019 filing shows 32 new, 25 increased, 31 reduced and 26 closed positions. Its largest new stake was Pareteum Corporation: 2,248,578 shares worth $2.9M. The largest sale was Ampio Pharmaceuticals Inc., an estimated $2.04M.

By sector, the portfolio is most concentrated in Healthcare at 15% of assets, down from 37% a quarter earlier, followed by Technology and Industrials.

  • Sabby Management's largest Q3 2019 buy was Pareteum Corporation: 2,248,578 shares worth $2.9M.
  • Sabby Management added most to Advaxis Inc in Q3 2019, an estimated $1.01M increase.
  • Sabby Management's biggest Q3 2019 reduction was Odonate Therapeutics, Inc. Common Stock, cutting an estimated $1.35M.
  • Sabby Management fully exited Ampio Pharmaceuticals Inc. in Q3 2019, selling an estimated $2.04M.
  • Sabby Management's ten largest holdings make up 78% of its $186M portfolio in Q3 2019.
  • Sabby Management opened 32 new positions and closed 26 in Q3 2019.
  • Sabby Management's portfolio value rose 133% quarter-over-quarter to $186M.

Based on Sabby Management's 13F filing for Q3 2019, filed 15 Nov 2019.